Skip to main content
. Author manuscript; available in PMC: 2023 Jun 13.
Published in final edited form as: Cancer Cell. 2022 May 26;40(6):609–623.e6. doi: 10.1016/j.ccell.2022.05.005

Figure 7. Impact of subtyping schema on minimum required efficacy of new agent (HER2low example).

Figure 7.

a) Sankey plot showing a variety of ways to combine HER2low status with HR and Immune/DRD. b) Scatter plot showing prevalence of HER2low subsets (x-axis) vs. the minimum pCR rate required for an anti-HER2low agent to equal that of the I-SPY2 agent with the highest response (minimum efficacy; y-axis).